Full-Time

Senior Vice President

Corporate Communications

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

Compensation Overview

$325k - $375k/yr

+ Bonus + Equity

Expert

No H1B Sponsorship

San Francisco, CA, USA

Requires 4 days a week onsite.

Category
PR & Communications
Growth & Marketing
Required Skills
Social Media
Requirements
  • 18+ years of proven experience in leadership roles within corporate communications and public relations, with a minimum of 10 years in biotech/pharmaceuticals.
  • Bachelor’s degree in communications, Public Relations, Marketing, or a related field; advanced degree preferred.
  • Demonstrated experience crafting and executing successful traditional media, social media, and internal communications strategies.
  • Exceptional written and verbal communication skills.
  • Understanding of SEC and FDA regulations impacting communications.
  • Experience in crisis communication and issues management.
  • Demonstrated ability to build and maintain strong relationships with media, stakeholders, and key industry influencers, including existing relationships with top-tier media and journalists.
  • Strong leadership skills and the ability to inspire and mentor a team.
Responsibilities
  • Develop and execute a comprehensive communications roadmap that seamlessly aligns with Vir Biotechnology’s business objectives and propels our positioning as a global biotech leader.
  • Serve as the primary strategic business partner to the CEO on all corporate communications matters, providing expert guidance and support to align communication strategies with overall business objectives.
  • Drive long-term strategic initiatives that support the company's vision and goals.
  • Design and implement internal communication strategies that enhance employee engagement and alignment, particularly during periods of transformation.
  • Collaborate with HR to integrate communication strategies with change management initiatives, ensuring a unified message throughout the organization.
  • Partner with Finance and Investor Relations to lead preparations for earnings calls with a focus on messaging, press release and website updates.
  • Establish a strong and compelling executive/c-suite voice to represent Vir Biotechnology both internally and externally.
  • Prepare company spokespeople for media interviews and other engagements, including training spokespeople, as needed, and ensuring that company’s most frequent spokespeople are prepared to address key issues as they emerge.
  • Craft high-impact communication materials and foster relationships with top-tier media and journalists to elevate the company’s profile.
  • Develop and lead initiatives to promote and safeguard Vir Biotechnology’s brand and reputation, managing media relations and acting as the company spokesperson.
  • Build and enhance relationships with external media outlets including news, business, and industry trade publications, with both traditional and digital media; garner local, regional and national coverage to meet objectives.
  • Oversee the development of all public relations materials, collaborating with internal and external stakeholders.
  • Recommend external opportunities, including media interviews, speaking engagements at industry conferences, and other forums to showcase thought leadership.
  • Define and manage the strategy, planning, and implementation of a robust social media presence.
  • Be the strategic hub for well-coordinated and organized communications across multiple internal groups. Work collaboratively with colleagues across the organization to ensure alignment and visibility of communications initiatives across functions.
  • Lead, inspire, develop and manage a Corporate Communications Team, including contractors, to deliver on goals and business results.
  • Develop crisis communication protocols and strategies to proactively address potential reputational risks and effectively manage crises if they arise.

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
  • The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
  • Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

What critics are saying

  • Leadership instability due to key executive resignations may disrupt operations.
  • Job cuts and facility closures indicate potential financial strain.
  • Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

What makes Vir Biotechnology unique

  • Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
  • The company focuses on immune system manipulation for targeted therapies.
  • Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

2%

2 year growth

1%
U.S. Securities and Exchange Commission
Dec 5th, 2024
vir-10q_20200331.htm

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Investing.com
Aug 1st, 2024
Vir Biotechnology inks major deal with Sanofi unit

Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.

MarketScreener
Aug 1st, 2024
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.

Simply Wall St
May 5th, 2024
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.

Investing.com
Apr 18th, 2024
Vir Biotechnology CFO Sung Lee to step down in May

Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.